Index for Medicine Volume 35

Medicine Index Volume 35:1–35:12

A abdominal pain 35:3, 139 abrin 35:10, 577 accidental ingestion 35:10, 547 acetaminophen see paracetamol acetone poisoning 35:11, 581 acetylcholinesterase (AChE) 35:10, 573 acid–base 35:7, 368 disturbances in poisoning 35:10, 548, 559 excretion 35:7, 369 see also metabolic acidosis; metabolic alkalosis acne vulgaris 35:8, 475 acromegaly, treatment 35:2, 125 activated charcoal 35:10, 560 salicylate poisoning 35:12, 655 theophylline poisoning 35:12, 657 acute fatty liver of pregnancy 35:2, 73 acute renal failure 35:7, 353 atheromatous renovascular disease 35:7, 407 management 35:8, 434 NSAID-induced 35:7, 399 patient assessment 35:8, 429 post-renal 35:8, 431 pre-renal 35:8, 430, 431 adverse drug reactions 35:9, 501 acute interstitial nephritis 35:9, 500 acute renal failure 35:7, 354 cholestasis 35:1, 28 colitis 35:4, 213 constipation 35:4, 212 diarrhoea 35:4, 213 gastrointestinal disorders 35:4, 210 glomerular diseases 35:9, 498 interstitial nephritis 35:9, 500, 502 liver damage 35:1, 26 diagnosis 35:1, 29 liver disease clinical assessment 35:1, 1 susceptibility 35:1, 28 liver necrosis 35:1, 26, 27 malabsorption 35:4, 213, 225 microscopic colitis 35:5, 290

MEDICINE 36:I

nausea and vomiting 35:4, 212 NSAIDs 35:4, 207, 208, 210, 211, 214 pancreatitis 35:4, 212 small intestinal injury 35:4, 213 steatosis 35:1, 26, 27 ulcerative colitis 35:4, 214 affective disorder with substance use 35:4, 248 AIDS see HIV infection Alagille syndrome 35:2, 64 albuminuria 35:7, 362 alcohol consumption anxiety disorders 35:4, 248 colorectal cancer 35:6, 298 liver disease 35:1, 22 clinical assessment 35:1, 1 risk factors 35:1, 23 see also ethanol alcoholic hepatitis 35:1, 23, 24, 25 autoimmune hepatitis differential diagnosis 35:2, 77 liver transplantation 35:2, 112 alkylating agent precursors 35:12, 650 Alport’s syndrome 35:7, 390 aluminium phosphide 35:12, 648 aminoglycosides 35:7, 400 ammonia 35:2, 108 poisoning 35:11, 583 amphetamines 35:7, 402 poisoning 35:11, 582 ampullary tumors 35:2, 123 amyloidosis 35:9, 499, 514, 515 chronic renal failure 35:8, 441 anaemia 35:3, 142 chronic kidney disease 35:8, 457 iron deficiency 35:3, 142; 35:8, 459 macrocytic 35:3, 144 microcytic 35:3, 142 mouth disorders 35:4, 192 renal transplantation 35:9, 485 anal abscess 35:3, 150 anal canal, anatomy/physiology 35:3, 147 anal disorders 35:3, 148

anal fissure 35:3, 149 anal fistula 35:3, 150 anal sphincter 35:3, 147 anal tumours 35:3, 150 analgesics adjuvant 35:5, 293 maximal conservative management in kidney disease 35:8, 471 nephropathy 35:9, 502 Anderson–Fabry disease 35:7, 395 angina pain 35:3, 135 angiodysplasia 35:3, 164 anion gap 35:10, 548, 549 anogenital warts 35:7, 412 antibiotics gastrointestinal disorder induction 35:4, 210, 214 kidney damage 35:7, 400 urinary tract infection 35:8, 427 anticoagulant poisoning 35:12, 648, 664 anticonvulsant poisoning 35:11, 585 antidepressants irritable bowel syndrome 35:5, 270 poisoning 35:10, 538, 539; 35:11, 587 antidiabetic drugs, poisoning 35:11, 590 anti-glomerular basement membrane antibodies (antiGBM) 35:9, 494 antihistamine poisoning 35:11, 592 antihypertensive agents 35:8, 443 antimicrobial therapy, diarrhoea 35:5, 254 antimitochondrial antibodies 35:2, 79 antimuscarinic agents 35:12, 649 antineutrophil cytoplasmic antibodies (ANCA) 35:9, 494 antineutrophil cytoplasmic antibodies (ANCA)­associated vasculitis 35:9, 519, 520 antinuclear antibodies (ANA) 35:2, 76, 79 antiphospholipid antibody syndrome 35:9, 511





antipsychotic drugs, poisoning 35:11, 594 antireflux surgery 35:4, 197 antispasmodics 35:5, 269 α1-antitrypsin deficiency 35:2, 63 anxiety disorder, substance use 35:4, 248 aorta, angiography 35:3, 179 aortoduodenal fistula 35:3, 158 aortoenteric fistula 35:3, 165 aquatic animals, bites/stings 35:12, 661 argon plasma coagulation 35:6, 334 arterial blood volume, effective 35:7, 370, 371 arterial disease, hormone replacement therapy 35:9, 531 arterial occlusion, small bowel ischaemia 35:3, 178 arteriovenous malformations, upper gastrointestinal 35:3, 158 arthritis, non-septic/septic 35:5, 255 arthropod bites/stings 35:12, 660 ascites 35:1, 2; 35:2, 104 abdominal tuberculosis differential diagnosis 35:5, 259 renal dysfunction 35:9, 523 atheromatous renovascular disease 35:7, 407 atherosclerotic renovascular disease 35:7, 406 atomoxetine 35:3, 183 atropine nerve agent poisoning 35:10, 575 plant sources 35:12, 649 poisoning antidote 35:10, 562 attention deficit hyperactivity disorder (ADHD) 35:3, 181 adults 35:3, 184 treatment 35:3, 182 autoimmune hepatitis 35:2, 68, 75 autosomal dominant polycystic kidney disease (ADPKD) 35:7, 386 avascular necrosis of bone, renal transplantation 35:9, 484

© 2008 Published by Elsevier Ltd.

MEDICINE INDEX VOLUME 35 2007

B

β2-agonists, poisoning 35:11, 597 bacterial overgrowth 35:4, 223 bacteriuria asymptomatic 35:8, 428 pregnancy 35:8, 426, 428 Balkan nephropathy 35:9, 502 Barrett’s oesophagus 35:4, 201, 216 radio-frequency ablation 35:6, 334 β-blocker poisoning 35:11, 596 BCG vaccination 35:1, 56 Behçet’s syndrome 35:4, 193 benzodiazepine poisoning 35:11, 598 Berger’s disease 35:9, 493 bile duct carcinoma, primary sclerosing cholangitis 35:2, 83, 85 bile duct stones 35:2, 119 biliary atresia 35:2, 63 biliary cirrhosis, primary 35:2, 79 liver transplantation 35:2, 113 biliary colic 35:2, 116 biliary dyspepsia 35:2, 118 biliary parasites, tropical liver disease 35:1, 49 biliary tract tumours 35:2, 123 bilirubin, urinary 35:7, 367 biopsy liver 35:1, 10, 17, 20 renal image-guided 35:7, 382 bipolar disorder with substance use 35:4, 248 bladder abnormal 35:8, 428 neuropathic 35:8, 448 bleaches, poisoning 35:11, 621 bleeding, abnormal, poisoning 35:10, 541 blistering agents 35:10, 578 bloating 35:3, 140 body fluid compartments 35:7, 371 body mass index (BMI), alcoholic liver disease 35:1, 24 bone disease, metabolic high-turnover 35:8, 450 low-turnover 35:8, 450 renal 35:8, 450 renal transplantation 35:9, 484 see also osteoporosis bone mineral density, DepoProvera® use 35:6, 350, 351 bowel cancer, hormone replacement therapy 35:9, 531 breast cancer, hormone replacement therapy 35:9, 530 British anti-lewisite 35:10, 563 Budd–Chiari syndrome 35:2, 102 bullous disorders, mouth 35:4, 190 buprenorphine 35:5, 293; 35:12, 641

MEDICINE 36:I

C

neuropathic bladder 35:8, 448 pelvi-ureteric junction obstruction 35:8, 447 poisoning 35:10, 538, 541, 543 hospital admission 35:10, 559 posterior urethral valves 35:8, 447, 448 primary sclerosing cholangitis 35:2, 69 prune belly syndrome 35:8, 448 renal disorders 35:7, 393 renal stone disease 35:8, 449 urinary tract infection 35:8, 427 vesico-ureteric reflux 35:7, 387 viral hepatitis 35:2, 67, 68 Chinese herbs nephropathy 35:9, 502 Chlamydia screening 35:7, 412 chlorine poisoning 35:11, 606 chloroquine poisoning 35:12, 652 chlorphenoxyacetate herbicides 35:12, 648 cholangiocarcinoma 35:2, 124 cholecystectomy 35:2, 119 cholecystitis 35:2, 116 chronic 35:2, 118 pain 35:3, 134 cholestasis complications 35:2, 96 drug-induced 35:1, 28 infantile 35:2, 61 multifactorial in premature infants 35:2, 64 obstetric 35:2, 72 primary sclerosing cholangitis 35:2, 83 progressive familial intra­ hepatic 35:2, 64 chromendoscopy 35:6, 331 chronic intestinal pseudoobstruction (CIPO) 35:5, 275 chronic kidney disease (chronic renal failure) 35:7, 355; 35:8, 438 anaemia 35:8, 457 bone metabolism biochemical targets 35:8, 451 cardiovascular complications 35:8, 453 children 35:8, 441 urological disorders progressing to 35:8, 447 developing countries 35:8, 441 hypertension 35:7, 404 management 35:8, 442 neuropathic bladder 35:8, 448 pelvi-ureteric junction obstruction 35:8, 447 posterior urethral valves 35:8, 447, 448 proteinuric 35:8, 445

cadmium, kidney damage 35:7, 401 calcification, extra-skeletal 35:8, 450 calcineurin inhibitor toxicity 35:9, 502 calcium channel blockers, poisoning 35:11, 599 calcium ions, poisoning 35:10, 551 calcium oxalate crystals 35:12, 649 Candida oesophagitis 35:4, 210 candidiasis oesophageal 35:5, 262 oral 35:4, 192 cannabis poisoning 35:11, 603 carbamate insecticides 35:12, 647 carbon monoxide poisoning 35:11, 604 carboxyhaemoglobin 35:11, 604 cardiac glycosides 35:11, 613 cardiotoxic steroids 35:12, 649 cardiovascular disease chronic kidney disease 35:8, 453 hormone replacement therapy 35:9, 531 renal transplantation 35:9, 484 uraemia 35:8, 454 cardiovascular function, poisoning 35:10, 558 cathartics 35:10, 560 catheter infections 35:9, 508 urinary tract infection 35:8, 426 caustic injury, oesophageal 35:3, 156 coeliac disease 35:4, 191 cervical cancer, vaccines 35:1, 57 chemical terrorism 35:10, 573 abrin 35:10, 577 nerve agents 35:10, 573 ricin 35:10, 576 sulphur mustard 35:10, 578 chemotherapy colorectal cancer 35:6, 309 kidney damage 35:7, 400 oesophageal tumours 35:4, 202 oral mucositis 35:4, 193 paraprotein-related renal disease 35:9, 512 Chikungunya fever 35:1, 54 Child–Pugh score 35:2, 113 children attention deficit hyperactivity disorder 35:3, 181 chronic renal failure 35:8, 441 urological disorders progressing to 35:8, 447 cirrhosis 35:2, 69 liver disease 35:2, 67 liver transplantation 35:2, 70 liver tumours 35:2, 70



prune belly syndrome 35:8, 448 renal stone disease 35:8, 449 staging 35:7, 359 therapeutic levers 35:8, 452 ciclosporin, ulcerative colitis 35:5, 280 circulation, assessment in poisoning 35:10, 543 cirrhosis alcoholic 35:1, 23, 25; 35:9, 523 ascites 35:2, 104 assessment 35:1, 12 children 35:2, 69 haemodynamic events 35:9, 521, 522 variceal bleeding 35:2, 99 see also biliary cirrhosis, primary cisplatinum 35:7, 400 Clostridium difficile antibiotic use 35:4, 210, 214 drug resistance 35:1, 54 cocaine 35:7, 402 poisoning 35:11, 607 codeine 35:12, 641 coeliac disease 35:4, 226 malignancy 35:4, 228 optical technology for detection 35:6, 331 refractory 35:4, 229 colitis diarrhoea 35:5, 252 diverticular 35:6, 319 drug-induced 35:4, 213 microscopic 35:5, 290 see also ulcerative colitis colon bleeding 35:3, 164 malfermentation 35:5, 269 microflora damage 35:5, 268 motility 35:5, 272 irritable bowel syndrome 35:5, 274 toxic dilatation 35:3, 168 colonic disease Crohn’s disease differential diagnosis 35:5, 287 right-sided 35:3, 158 colorectal cancer 35:6, 297 early diagnosis 35:6, 300 early disease 35:6, 306 locally advanced disease 35:6, 307 management 35:6, 306 metastases 35:6, 308 pathology/pathogenesis 35:6, 302 preoperative assessment 35:6, 306 prevention 35:6, 298, 299, 300 screening 35:6, 299, 304 staging 35:6, 302 colostomy 35:6, 314 coma, unexplained in absence of head injury 35:10, 540 complement in glomerulo­ nephritis 35:9, 490 complementary medicines

© 2008 Published by Elsevier Ltd.

MEDICINE INDEX VOLUME 35 2007

kidney damage 35:7, 401 see also traditional medicines computed tomography (CT), renal 35:7, 378, 380, 381 confocal microendoscopy 35:6, 331 confusional states 35:10, 540 congenital hepatic fibrosis 35:2, 69 conscious level, poisoning 35:10, 542 constipation 35:3, 137 drug-induced 35:4, 212 slow-transit 35:5, 275 contraception 35:6, 348 emergency 35:6, 350 long-acting reversible 35:6, 348 UK Medical Eligibility Criteria 35:6, 348, 349 contrast-induced nephrotoxicity 35:7, 400 convulsions, poisoning 35:10, 540, 558 copper poisoning 35:11, 608 transport 35:2, 93 corrosives, poisoning 35:11, 609 creatinine/creatinine clearance 35:7, 361 Crohn’s disease 35:5, 283 abdominal tuberculosis differential diagnosis 35:5, 258 liver disease 35:5, 286 mouth disorders 35:4, 191 symptoms/signs 35:3, 141 cryoglobulinemic renal disease 35:9, 508, 514 cryptosporidiosis 35:5, 262 cyanide poisoning 35:10, 563; 35:11, 612 plant compounds 35:12, 650 cyanogenic compounds, plant 35:12, 650 cyclo-oxygenase 2 (COX-2) inhibitors, gastrointestinal ulcers 35:4, 211 cystatin C 35:7, 362 cystic fibrosis 35:2, 69 cystinosis 35:7, 393 cystitis acute 35:8, 425, 427 chronic 35:8, 426 idiopathic 35:8, 426 cytomegalovirus (CMV) 35:5, 262 children 35:2, 67

D darbepoetin alfa 35:8, 459 dehydroepiandrosterone (DHEA) 35:2, 126 DepoProvera® 35:6, 350, 351 dermatitis herpetiformis 35:4, 228 desferrioxamine, poisoning antidote 35:10, 562 detergent poisoning 35:11, 620 developing countries, chronic renal failure 35:8, 441 dextropropoxyphene 35:12, 641

MEDICINE 36:I

duodenal obstruction, pancreatitis 35:6, 328 duodenal ulceration 35:3, 133; 35:4, 206, 207 duodenitis 35:3, 158 dysentery 35:5, 252, 253 dyslipidaemia chronic kidney disease 35:8, 444 renal transplantation 35:9, 484 dyspepsia 35:4, 206 angina differential diagnosis 35:3, 135 drug-induced 35:4, 211 non-ulcer 35:3, 133; 35:4, 207, 208 NSAID 35:4, 208 ulceration 35:4, 208 dysphagia 35:3, 154

diabetes mellitus alcoholic liver disease 35:1, 24 renal transplantation 35:9, 484 diabetic nephropathy 35:8, 440; 35:9, 503 diamorphine addiction 35:12, 641 poisoning 35:12, 640 diarrhoea 35:3, 136 acute watery 35:5, 252, 253 antimicrobial therapy 35:5, 254 bacterial 35:5, 262 bloody 35:5, 252 colitis 35:5, 252 complications 35:5, 255 drug-induced 35:4, 213 infectious 35:5, 251 persistent 35:5, 252, 253 diazepam cocaine poisoning 35:11, 607 nerve agent poisoning 35:10, 575 poisoning 35:11, 598 dicobalt edetate 35:10, 563 diethylene glycol poisoning 35:11, 617 Dieulafoy’s lesion 35:3, 158 digital subtraction angiography (DSA), renal 35:7, 380 digoxin poisoning 35:11, 613 digoxin-specific antibody fragments 35:10, 563 dihydrocodeine 35:12, 641 dimercaprol 35:10, 563 dipstick urinalysis, abnormal 35:7, 365 disaccharidase deficiencies 35:4, 225 disc battery poisoning 35:11, 621 disinfectant poisoning 35:11, 621 diverticular colitis 35:6, 319 diverticular disease 35:3, 164; 35:6, 317 diverticulitis 35:6, 317 diverticulosis 35:6, 317 drain cleaner poisoning 35:11, 621 drugs glomerular diseases 35:9, 498 hepatotoxic 35:1, 32 kidney damage 35:7, 399 loading dose 35:7, 396 maintenance dose 35:7, 396 novel 35:1, 55 poisoning 35:10, 537, 538, 539, 547 prescribing in liver disease 35:1, 31 renal insufficiency 35:7, 396 renal transplantation 35:9, 485 resistance 35:1, 54 tuberculosis 35:1, 56 see also adverse drug reactions; substance use/misuse

E eating disorders 35:9, 502 Ecstasy 35:7, 402; 35:11, 582 effective arterial blood volume (EABV) 35:7, 370, 371 eflornithine cream 35:2, 126 elastic scattering spectroscopy (ESS) 35:6, 331 electrolytes 35:7, 368 disorders 35:7, 368 poisoning 35:10, 550, 559 emesis 35:10, 560 empyema 35:2, 117 encephalopathy uraemic 35:8, 436 see also hepatic encephalopathy endocrinology advances 35:2, 125 endoscopic mucosal resection 35:6, 333 endoscopy ablative therapies 35:6, 334 diagnostic 35:6, 330 enteral nutrition 35:6, 335 lower gastrointestinal disease 35:6, 343 novel technologies 35:6, 330 therapeutic 35:6, 333 upper gastrointestinal disease 35:4, 241 end-stage renal disease atheromatous renovascular disease 35:7, 407 maximal conservative management 35:8, 470 enteral nutrition 35:4, 232 endoscopy 35:6, 335 enterocystoplasty 35:8, 428 enteropathy-associated T-cell lymphoma (EATL) 35:4, 228 episcleritis, inflammatory bowel disease 35:3, 141 Epstein–Barr virus (EBV), children 35:2, 67 erythema multiforme 35:4, 190 erythema nodosum 35:3, 141 erythropoietin 35:8, 457 renal anaemia treatment 35:8, 458



ethanol 35:10, 563 poisoning 35:11, 615 see also alcohol consumption ethylene glycol poisoning 35:11, 617 exercise colorectal cancer 35:6, 298 renal transplantation 35:9, 484

F Fabry disease 35:7, 395 faecal incontinence 35:3, 151 fat malabsorption, cholestasis 35:2, 97 fatigue, cholestasis 35:2, 96 fatty liver 35:1, 22, 25 acute of pregnancy 35:2, 73 fatty liver disease, non­alcoholic 35:2, 86 fentanyl poisoning 35:12, 641 transdermal 35:5, 292 fentanyl citrate, oral transmucosal 35:5, 292 ferroportin disease 35:2, 90 fetus, renal disease effects 35:9, 527 fibromuscular disease of the renal arteries 35:7, 406 fish, venomous 35:12, 661 fluid balance 35:4, 231 disorders 35:7, 368 poisoning 35:10, 559 flumazenil 35:10, 563 fluorescence imaging 35:6, 330, 331 focal necrotizing glomerulo­ nephritis 35:9, 494 focal nodular hyperplasia 35:2, 123 focal segmental glomerulosclerosis 35:9, 492, 498 HIV infection 35:9, 508 folate deficiency 35:3, 145 mouth disorders 35:4, 192 fomepizole 35:10, 563 formula feeds 35:4, 232 fractional resurfacing, laser 35:8, 474 free immunoglobulin light chains (FLC) 35:9, 512 fulminant hepatic failure 35:2, 110 liver transplantation 35:2, 113 fungal toxins 35:12, 635

G gall bladder cancer 35:2, 124 gallstones 35:2, 116 gamma-hydroxybutyric acid 35:11, 619 garden substances 35:10, 547 Gardener’s syndrome 35:4, 191 gastric antral vascular ectasia 35:3, 158 gastric cancer 35:4, 216 gastric emptying 35:5, 265 gastric lavage 35:10, 560 gastric leiomyoma 35:4, 219 gastric lymphoma 35:4, 218

© 2008 Published by Elsevier Ltd.

MEDICINE INDEX VOLUME 35 2007

gastric tumours 35:4, 216 gastric ulceration 35:3, 133; 35:4, 207 gastritis 35:3, 158 classification 35:4, 205 H. pylori 35:4, 204 prevention 35:4, 209 gastroduodenal erosions 35:3, 158 gastroduodenal ulcers, druginduced 35:4, 211 gastroenteritis, irritable bowel syndrome 35:5, 268 gastrointestinal absorption normal 35:4, 220 see also malabsorption gastrointestinal bleeding acute lower 35:3, 164 acute upper 35:3, 157 endoscopy 35:6, 333 lower 35:3, 138 non-variceal 35:3, 161, 162 portal hypertension 35:2, 99 variceal 35:3, 163 vascular anomalies 35:3, 158 gastrointestinal disease, immunodeficiency 35:5, 261 gastrointestinal disease, lower endoscopy 35:6, 343 extra-intestinal signs 35:3, 140 radiology 35:6, 337 symptoms/signs 35:3, 136 gastrointestinal disease, upper endoscopy 35:4, 241 malignancy 35:3, 133 radiology 35:4, 236 symptoms/signs 35:3, 131 gastrointestinal disorders, drug-induced 35:4, 210 gastrointestinal stromal tumour 35:4, 219 gastro-oesophageal reflux disease (GORD) 35:3, 131; 35:4, 194 mouth disorders 35:4, 192 reflux mechanisms 35:4, 195 gastro-oesophageal tumours 35:4, 199 genital HPV vaccine 35:7, 412 Giardia lamblia 35:5, 261 glomerular diseases 35:7, 390 infection-associated 35:9, 497 primary 35:9, 489 secondary 35:9, 497 tumour-associated 35:9, 497 glomerular filtration rate 35:7, 359, 363 progressive loss 35:8, 443 glomerulonephritis 35:7, 355; 35:9, 489 chronic renal failure 35:8, 440 hepatitis B virus 35:8, 441; 35:9, 508

MEDICINE 36:I

hepatitis C virus 35:9, 508 membranous 35:8, 441; 35:9, 498, 508 mesangiocapillary 35:9, 499, 507 hepatitis B virus 35:9, 508 post-infectious 35:9, 499 post-streptococcal 35:8, 441; 35:9, 507 rapidly progressive 35:9, 518, 519 subtypes 35:9, 491 glossitis 35:4, 189, 191 glucagon 35:10, 563 glucagon-like peptide-1 (GLP-1) 35:2, 127 glucose homeostasis 35:10, 551 urine testing 35:7, 366 glutamine–glutamate cycle 35:2, 108 gluten 35:4, 226 restriction 35:4, 228, 229 glycaemic control chronic kidney disease 35:8, 444 diabetic nephropathy 35:9, 505 Gold Standards Framework (GSF) 35:5, 294 gonorrhoea 35:7, 410 Goodpasture’s syndrome 35:9, 494 growth hormone, weekly 35:2, 125 Guillain–Barré syndrome 35:5, 255 gut motility 35:5, 272

Helicobacter pylori 35:4, 204, 216 eradication 35:4, 208 management 35:4, 206 NSAIDs association 35:4, 211, 208 optical technology for detection 35:6, 331 HELLP syndrome 35:2, 73 Henoch–Schönlein purpura 35:7, 357 hepatic encephalopathy 35:1, 3; 35:2, 108 hepatic failure, fulminant 35:2, 110 liver transplantation 35:2, 113 hepatic fibrosis, congenital 35:2, 69 hepatitis alcoholic 35:1, 23, 24, 25 autoimmune 35:2, 68, 75 neonatal 35:2, 61 pregnancy 35:2, 72 tropical liver disease 35:1, 49 viral in children 35:2, 67, 68 hepatitis A virus 35:1, 33 children 35:2, 67 hepatitis B virus 35:1, 39 children 35:2, 67, 68 chronic 35:1, 39 clinical assessment 35:1, 1 clinical features 35:1, 41 glomerulonephritis 35:8, 441; 35:9, 508 management 35:1, 41 hepatitis C virus 35:1, 43; 35:7, 411 children 35:2, 68 clinical assessment 35:1, 1 clinical features 35:1, 44 cryoglobulinemic renal disease 35:9, 508, 514 laboratory features 35:1, 44 liver transplantation 35:2, 112 management 35:1, 45 renal disease 35:9, 508 hepatitis D virus 35:1, 39 hepatitis E virus 35:1, 37 children 35:2, 67 hepatobiliary isotope scanning 35:1, 8 hepatobiliary tumours 35:1, 52; 35:2, 121 hepatocellular carcinoma 35:2, 123 liver transplantation 35:2, 113 hepatorenal syndrome 35:9, 521, 522, 523 hepatosplenomegaly 35:1, 3 hepatotoxic drugs 35:1, 32 hereditary haemochromatosis 35:2, 89 hereditary haemorrhagic telangiectasia 35:4, 193 heroin 35:7, 402 injection 35:10, 571, 570



H haemangioma 35:2, 122 haematuria 35:7, 365, 366 glomerular 35:7, 390 persistent asymptomatic 35:7, 390 haemochromatosis 35:2, 89 juvenile 35:2, 90 haemodiafiltration 35:8, 463 haemodialysis 35:8, 461 complications 35:8, 464 high-flux 35:8, 463 peritoneal dialysis comparison 35:8, 468 poisoning management 35:10, 561 haemofiltration 35:8, 463 haemoglobinuria 35:7, 365 haemolytic–uraemic syndrome 35:5, 255; 35:9, 510 haemoperfusion, poisoning management 35:10, 561 haemorrhoids 35:3, 148 hair removal, laser 35:8, 474 hantavirus 35:9, 509 heart disease, ischaemia, pain 35:3, 135 heartburn, drug-induced 35:4, 210 heavy metals, kidney damage 35:7, 401; 35:9, 502



herpes simplex, oral 35:4, 192 HI-6 35:10, 563 hiatus hernia 35:4, 194 highly active antiretroviral therapy (HAART) 35:5, 261; 35:9, 508 hirsutism 35:2, 126 HIV infection immune complex diseases 35:9, 509 immunodeficiency 35:5, 261 renal disease 35:9, 508 tuberculosis 35:5, 257 HIV nephropathy 35:8, 441 hormone replacement therapy 35:9, 529 cardiovascular disease 35:9, 531 malignancy 35:9, 530 vasomotor symptoms 35:9, 529 Window of Opportunity theory 35:9, 531 household products, poisoning 35:10, 547; 35:11, 620 human papilloma virus (HPV) vaccine 35:7, 412 hydatid disease of liver 35:1, 52 hydrocarbons, kidney damage 35:7, 401 hydrogen sulphide, poisoning 35:12, 623 hydroxycobalamin 35:10, 563 5-hydroxytryptamine (5-HT) antagonists/agonists 35:5, 269 hyoscyamine 35:12, 649 hyperemesis gravidarum, liver dysfunction 35:2, 72 hyperkalaemia 35:7, 373, 375 acute renal failure 35:8, 435 poisoning 35:10, 550, 551 hyperkinetic disorder 35:3, 181 hypernatraemia 35:7, 370 poisoning 35:10, 550 hyperoxaluria, primary type I 35:7, 395 hyperparathyroidism 35:8, 450 hypertension diabetic nephropathy 35:9, 504 intraglomerular 35:8, 443 renal disease 35:7, 404; 35:8, 443 renal transplantation 35:9, 484 systemic 35:8, 443 hypocalcaemia, poisoning 35:10, 551 hypoglycemia, poisoning 35:10, 540 hypokalaemia 35:7, 373, 374 poisoning 35:10, 550 hyponatraemia 35:2, 127; 35:7, 370 poisoning 35:10, 550 hypothermia, poisoning 35:10, 559

© 2008 Published by Elsevier Ltd.

MEDICINE INDEX VOLUME 35 2007

I ifosphamide 35:7, 400 IgA nephropathy 35:9, 493 alcoholic cirrhosis association 35:9, 523 ileal pouch 35:6, 311 dysfunction 35:6, 312 ileostomy 35:6, 311, 314 complications 35:6, 315 ileus, postoperative 35:5, 275 image-guided biopsy, renal 35:7, 382, 384, 385 immune complex diseases, HIV-associated 35:9, 509 immunobullous disorders, mouth 35:4, 190 immunodeficiency gastrointestinal disease 35:5, 261 malabsorption 35:4, 224 immunoglobulins 35:9, 512 immunosuppression, renal transplantation 35:9, 483, 485, 486 incontinence, faecal 35:3, 151 infantile cholestasis 35:2, 61 multifactorial in premature infants 35:2, 64 infants Alagille syndrome 35:2, 64 α1-antitrypsin deficiency 35:2, 63 biliary atresia 35:2, 63 liver disease 35:2, 61 progressive familial intrahepatic cholestasis 35:2, 64 infections/infectious diseases 35:1, 54 acute interstitial nephritis 35:9, 500 catheter 35:9, 508 emergent 35:1, 54 glomerular diseases 35:9, 497 immune deficiency­associated 35:5, 261 liver disease 35:9, 522 renal transplantation 35:9, 486 shunt 35:9, 508 systemic causing renal disease 35:9, 507 infective endocarditis 35:9, 508 inferior mesenteric artery, occlusion/stenosis 35:3, 178 inflammatory bowel disease 35:3, 140 see also Crohn’s disease; ulcerative colitis inflammatory disease, multisystem, tubulo-interstitial nephritis 35:9, 501 infliximab, ulcerative colitis 35:5, 280 insect stings 35:12, 661 interstitial nephritis acute 35:9, 500 chronic 35:9, 500, 502 intestinal failure 35:4, 231 intestinal lymphangiectasia 35:4, 224

MEDICINE 36:I

intestinal transplantation 35:4, 234 intravenous urogram (IVU) 35:7, 377 intrinsic glomerular cells, glomerulonephritis 35:9, 491 iron deficiency anaemia 35:3, 142; 35:8, 459 iron poisoning 35:12, 624 iron supplements, renal anaemia 35:8, 459 irritable bowel syndrome (IBS) 35:5, 267 diarrhoea 35:5, 256 gas excretion 35:5, 270 gut motility 35:5, 274 isopropanol, poisoning 35:12, 626 isotope studies, renal 35:7, 381

light chain deposition disease 35:9, 514 liquid nitrogen 35:12, 638 lithium 35:7, 400 poisoning 35:12, 629 toxicity 35:9, 502 liver donation 35:2, 114 drug damage 35:1, 26 drug metabolism 35:1, 31 fibrosis 35:1, 23, 24 histological assessment 35:1, 17 investigations 35:1, 5 metastases 35:1, 9; 35:2, 70, 123 necrosis 35:1, 26, 27 liver abscess, tropical liver disease 35:1, 51 liver biopsy 35:1, 10, 17 interpretation 35:1, 20 liver cell adenoma 35:2, 123 liver disease acute in children 35:2, 67 alcohol consumption 35:1, 1, 22 alcoholic 35:2, 77 liver transplantation 35:2, 112 children 35:2, 67 chronic 35:1, 21, 50; 35:2, 68 liver transplantation 35:2, 112 clinical assessment 35:1, 1 Crohn’s disease association 35:5, 286 drug pharmacodynamics 35:1, 32, 33 drug pharmacokinetics 35:1, 31 hereditary haemochromatosis 35:2, 90 hydatid disease 35:1, 52 infants 35:2, 61 infections 35:9, 522 metabolic 35:2, 69 non-hepatic 35:1, 3 physical examination 35:1, 2 pregnancy 35:2, 72 prescribing in 35:1, 31 renal dysfunction 35:9, 521, 523 tropical 35:1, 49 upper gastrointestinal bleeding 35:3, 159 liver failure fulminant 35:2, 110 liver transplantation 35:2, 113 paracetamol poisoning 35:12, 643 liver function biochemical tests 35:1, 5, 11 dynamic tests 35:1, 7 imaging 35:1, 7 poisoning 35:10, 540 liver transplantation 35:1, 24; 35:2, 112 children 35:2, 70 hepatic encephalopathy 35:2, 110

J Japanese encephalitis 35:1, 54 jaundice conjugated 35:1, 13 gallstones 35:2, 117 investigation 35:1, 13 liver disease clinical assessment 35:1, 2 obstructive 35:2, 119 pancreatitis 35:6, 328 tropical liver disease 35:1, 49 unconjugated 35:1, 13

K ketones, urine testing 35:7, 366 kidney acute injury (see acute renal failure) chronic infection 35:8, 426 cystic disorders 35:7, 388 drugs damaging 35:7, 399 function assessment 35:7, 359 imaging 35:7, 377 toxins 35:7, 401 kidney disease see acute renal failure; chronic kidney disease

L lactase deficiency 35:4, 225 lactic acidosis, poisoning 35:10, 548 laser therapy for dermatological conditions 35:8, 473 fractional resurfacing 35:8, 474 optical clearing agents 35:8, 476 pneumatic suction devices 35:8, 476 laxatives 35:4, 213 lead kidney damage 35:7, 401 poisoning 35:12, 627 leptospirosis 35:9, 509 leucopenia, renal transplantation 35:9, 485 leukocyte esterase 35:7, 365 lichen planus 35:4, 191





primary biliary cirrhosis 35:2, 82 liver tumours benign 35:2, 121 children 35:2, 70 malignant 35:2, 123 Liverpool Integrated Care Pathway 35:5, 294 LSD (lysergic acid diethylamide) poisoning 35:12, 631 lupus nephritis 35:9, 516 lymphangiectasia 35:4, 224 lymphogranuloma venereum 35:7, 410 lymphoma coeliac disease 35:4, 228 malabsorption 35:4, 225 tumour-associated glomerular diseases 35:9, 497

M macrocytic anaemia 35:3, 144 magnetic resonance imaging (MRI), renal 35:7, 380 malabsorption 35:4, 220 abdominal tuberculosis differential diagnosis 35:5, 259 causes 35:4, 223 cholestasis 35:2, 97 drug-induced 35:4, 213, 225 post-infectious 35:4, 223 primary biliary cirrhosis 35:2, 81 malaria, renal disease 35:8, 441; 35:9, 509 malignancy coeliac disease 35:4, 228 hormone replacement therapy 35:9, 530 paraprotein-related renal disease 35:9, 512 renal transplantation 35:9, 485 stomach 35:3, 158 tumour-associated glomerular diseases 35:9, 497 ulcerative colitis 35:5, 281 upper gastrointestinal tract 35:3, 133 Mallory–Weiss tear 35:3, 154, 157 MALToma 35:4, 218 maximal conservative management, renal disease 35:8, 470 MDMA 35:11, 582 LSD combination 35:12, 631 Mediterranean lymphoma, malabsorption 35:4, 225 melanosis coli 35:4, 213 membranous glomerulonephritis 35:9, 498 hepatitis B virus 35:9, 508 hepatitis C virus 35:9, 508 membranous nephropathy 35:9, 493 Mental Capacity Act (2005) 35:5, 293 mercury

© 2008 Published by Elsevier Ltd.

MEDICINE INDEX VOLUME 35 2007

kidney damage 35:7, 401 poisoning 35:12, 632 mesangiocapillary glomerulonephritis 35:9, 493, 499, 507 hepatitis B virus 35:9, 508 mesenteric ischaemia, pain 35:3, 134 mesenteric venous thrombosis 35:3, 178 metabolic acidosis 35:7, 375 acute renal failure 35:8, 436 chronic kidney disease 35:8, 445 poisoning 35:10, 541, 548 metabolic alkalosis 35:7, 375; 35:10, 550 metabolic bone disease renal transplantation 35:9, 484 see also osteoporosis metastases colorectal cancer 35:6, 308 liver 35:1, 9; 35:2, 123 children 35:2, 70 methadone 35:12, 641 methaemoglobin formation 35:10, 563 methaemoglobinaemia 35:10, 552 methanol poisoning 35:12, 633 methicillin-resistant Staphylococcus aureus (MRSA) 35:1, 55 methylioninium chloride (methylene blue) 35:10, 563 methylmalonic aciduria 35:7, 394 methylphenidate 35:3, 183 modified release 35:3, 182 microangiopathies 35:9, 510 thrombotic 35:9, 509 microcytic anaemia 35:3, 142 microsporidiosis 35:5, 262 migratory motor complex 35:5, 273 minimal-change nephropathy 35:9, 491 Mirizzi syndrome 35:2, 118 mitotic inhibitors 35:12, 650 morphine addiction 35:12, 641 poisoning 35:12, 640 mouth disorders 35:4, 189 bullous 35:4, 190 infective 35:4, 192 vascular 35:4, 193 mucocele 35:2, 117 multiple myeloma 35:9, 512 Munchausen syndrome-byproxy 35:10, 541 mushrooms, poisoning 35:12, 635 Mycobacterium avium–intracellulare complex 35:5, 262 Mycoplasma genitalium 35:7, 410 myeloma cast nephropathy 35:9, 513

MEDICINE 36:I

N

oesophageal sphincter, lower/ upper 35:5, 263 oesophageal squamous cell carcinoma 35:4, 199 oesophageal tumours 35:4, 199 oesophageal ulcer 35:3, 154 immunodeficiency 35:5, 262 oesophagitis 35:3, 154, 157 Candida 35:4, 210 oesophagogastric tumours 35:3, 158 oesophagogastric varices 35:3, 157 bleeding 35:3, 163 oesophagus caustic injury 35:3, 156 drug-induced mucosal injury/strictures 35:4, 210 infections 35:5, 262 motility 35:5, 263 peristalsis 35:5, 264 pH monitoring 35:4, 196 opiates 35:5, 269 opioid poisoning 35:12, 640 optical clearing agents 35:8, 476 optical coherence tomography 35:6, 331 oral candidosis 35:4, 192 oral disease medications 35:4, 190 primary 35:4, 189 secondary 35:4, 190 oral mucositis, chemotherapy 35:4, 193 oral rehydration solutions 35:4, 232 organic solvents, kidney damage 35:7, 401 organochlorine insecticides 35:12, 647 organophosphorus compounds nerve agents 35:10, 573 pesticides 35:12, 646 orofacial granulomatosis 35:4, 191 Osler–Weber–Rendu syndrome 35:4, 193 osmolality 35:7, 371 disorders with poisoning 35:10, 550 osteodystrophy 35:8, 451 osteopenia, primary biliary cirrhosis 35:2, 81 osteoporosis cholestasis 35:2, 96, 97 coeliac disease 35:4, 228 DepoProvera® risks 35:6, 350, 351 renal transplantation 35:9, 484 treatment 35:2, 126 ovarian cancer, hormone replacement therapy 35:9, 530 ovarian hyperstimulation syndrome 35:2, 73 over-the-counter medicines 35:7, 401 oximes, nerve agent poisoning 35:10, 575

naloxone 35:10, 563 narrow band imaging 35:6, 331 nausea and vomiting, druginduced 35:4, 212 neonatal hepatitis syndrome 35:2, 61 nephrolithiasis 35:8, 415 nephron 35:7, 368, 369 nephrotic syndrome 35:9, 490 nephro-urological problems, complex 35:8, 428 nerve agents 35:10, 573 nicotine-like alkaloids 35:12, 650 nitrites 35:7, 365 nitrogen/nitrogen oxide poisoning 35:12, 638 non-alcoholic fatty liver disease 35:2, 86 non-alcoholic steatohepatitis (NASH) 35:2, 69, 86 autoimmune hepatitis differential diagnosis 35:2, 77 non-steroidal anti-inflammatory drugs (NSAIDs) colorectal cancer prevention 35:6, 298 diverticular haemorrhage 35:3, 164 dyspepsia 35:4, 208, 211 gastrointestinal disorders 35:4, 210, 214 H. pylori association 35:4, 208, 211 kidney damage 35:7, 399 peptic ulcer 35:4, 207, 208, 211 poisoning 35:12, 639 small intestinal injury 35:4, 213

O obesity chronic kidney disease 35:8, 444 colorectal cancer 35:6, 298 renal transplantation 35:9, 484 treatment 35:2, 127 obidoxime 35:10, 563 obstetric cholestasis 35:2, 72 oesophageal adenocarcinoma 35:4, 199 oesophageal bleeding 35:3, 153, 157 vascular anomalies 35:3, 158 oesophageal body 35:5, 263 oesophageal cancer 35:4, 199 classification 35:4, 201 staging 35:4, 200 oesophageal candidiasis 35:5, 262 oesophageal disease, druginduced 35:4, 210 oesophageal emergencies 35:3, 153 oesophageal obstruction 35:3, 154 oesophageal perforation 35:3, 154



oxycodone 35:5, 293 oxygen 35:10, 563

P pain abdominal 35:3, 139 management in palliative care 35:5, 292 neuropathic 35:5, 293 pancreatic 35:3, 134; 35:6, 322, 328 poisoning patients 35:10, 559 upper gastrointestinal tract disease 35:3, 134 palliative care 35:5, 292 pancreatic cancer 35:6, 328 preferred place 35:5, 294 pancreatic cancer 35:6, 325 palliative care 35:6, 328 pancreatic necrosis 35:3, 175 pancreatic pain 35:3, 134; 35:6, 322, 328 pancreatitis acute 35:3, 171 chronic 35:6, 320 complications 35:3, 175 drug-induced 35:4, 212 scoring systems 35:3, 172, 173 severity 35:3, 173, 172, 174 paracentesis 35:2, 106 paracetamol poisoning 35:10, 545; 35:12, 643 paraproteins 35:9, 512 paraquat poisoning 35:12, 647 parasites, biliary, tropical liver disease 35:1, 49 parenteral nutrition 35:4, 233 pelvi-ureteric junction obstruction 35:8, 447 D-penicillamine, poisoning antidote 35:10, 562 peptic ulcer disease 35:3, 133; 35:4, 204 complicated 35:4, 208 perianal disorders, types 35:3, 148 pericarditis, uraemic 35:8, 436 pericolic abscess 35:6, 319 pericolitis 35:6, 319 peripheral oedema 35:1, 2 peritoneal dialysis 35:8, 466 pesticides, poisoning 35:12, 646 petroleum distillates, poisoning 35:11, 620 Peutz–Jeghers syndrome 35:4, 192 phenacetin, analgesic nephropathy 35:9, 502 photodynamic therapy 35:6, 334; 35:8, 475 photothermolysis, fractional 35:8, 475 phytomenadione 35:10, 563 plain radiographs, renal imaging 35:7, 377 plant toxins 35:10, 547; 35:12, 649 pneumatic suction devices 35:8, 476

© 2008 Published by Elsevier Ltd.

MEDICINE INDEX VOLUME 35 2007

pneumococcal disease vaccine 35:1, 57 poisoning 35:10, 535 absorption reduction 35:10, 560 accidental ingestion 35:10, 547 acetone 35:11, 581 ammonia 35:11, 583 amphetamines 35:11, 582 anticoagulants 35:12, 648, 664 anticonvulsants 35:11, 585 antidepressants 35:11, 587 antidiabetic drugs 35:11, 590 antidotes 35:10, 562 antihistamines 35:11, 592 antipsychotic drugs 35:11, 594 β2-agonists 35:11, 597 β-blockers 35:11, 596 benzodiazepines 35:11, 598 calcium channel blockers 35:11, 599 cannabis 35:11, 603 carbon monoxide 35:11, 604 causes 35:10, 537 chlorine 35:11, 606 chloroquine 35:12, 652 circulation 35:10, 543 clusters 35:10, 541 cocaine 35:11, 607 conscious level 35:10, 542 copper 35:11, 608 corrosives 35:11, 609 cyanide 35:10, 563; 35:11, 612 plant compounds 35:12, 650 diagnosis 35:10, 542 diethylene glycol 35:11, 617 digoxin 35:11, 613 elimination increase 35:10, 560 epidemiology 35:10, 537 ethanol 35:11, 615 ethylene glycol 35:11, 617 examination 35:10, 543 gamma-hydroxybutyric acid 35:11, 619 history 35:10, 543 hospital admission 35:10, 559 household products 35:10, 547; 35:11, 620 hydrogen sulphide 35:12, 623 iron 35:12, 624 isopropanol 35:12, 626 lead 35:12, 627 lithium 35:12, 629 low-toxicity ingestions 35:10, 547 LSD 35:12, 631 management 35:10, 558, 562 mercury 35:12, 632 metabolic effects 35:10, 548 methaemoglobinaemia 35:10, 552 methanol 35:12, 633 mortality 35:10, 538

MEDICINE 36:I

mushrooms 35:12, 635 nerve agents 35:10, 573 nitrogen/nitrogen oxides 35:12, 638 NSAIDs 35:12, 639 opioids 35:12, 640 paracetamol 35:10, 545; 35:12, 643 paraquat 35:12, 647 patient assessment 35:10, 542 pesticides 35:12, 646 plant toxins 35:10, 547; 35:12, 649 psychiatric assessment in deliberate self-poisoning 35:10, 565 quinine 35:12, 652 salicylates 35:12, 654 sulphur dioxide 35:12, 656 theophylline 35:12, 657 thyroxine 35:12, 658 toxins 35:10, 544 trial of antidotes 35:10, 544 triiodothyronine 35:12, 658 unexplained coma 35:10, 540 ventilation 35:10, 542 warfarin 35:10, 541, 563; 35:12, 648, 664 see also chemical terrorism; substance use/misuse polycystic kidney disease 35:7, 386, 387 portal hypertension 35:2, 99 portal hypertensive gastropathy 35:3, 158 posterior urethral valves 35:8, 447, 448 post-infectious glomerulo­ nephritis 35:9, 499 post-renal renal failure 35:7, 354 post-streptococcal glomerulonephritis 35:9, 507 post-traumatic stress disorder (PTSD), substance use 35:4, 248 potassium ions 35:7, 373 poisoning 35:10, 550, 551 pouchitis 35:6, 312 pralidoxime 35:10, 563 pregnancy acute fatty liver 35:2, 73 autosomal dominant polycystic kidney disease 35:7, 388 bacteriuria 35:8, 426, 428 liver disease 35:2, 72 renal disease 35:9, 524 thyroid hormones 35:2, 126 prematurity, multifactorial cholestasis 35:2, 64 prescribing in liver disease 35:1, 31 primary sclerosing cholangitis children 35:2, 69 liver transplantation 35:2, 113 pro-convulsants, plant 35:12, 650

progressive familial intrahepatic cholestasis (PFIC) 35:2, 64 prostatitis 35:8, 426, 427 protamine 35:10, 563 proteinuria 35:7, 362, 365, 367 pregnancy 35:9, 526 proton pump inhibitors (PPI) 35:3, 162 gastro-oesophageal reflux disease 35:4, 196, 197 prune belly syndrome 35:8, 448 pruritus cholestasis 35:2, 96, 97 primary biliary cirrhosis 35:2, 81 pruritus ani 35:3, 152 Prussian blue 35:10, 563 pseudo-obstruction, chronic intestinal 35:5, 275 psychiatric assessment, deliberate self-poisoning 35:10, 565 psychosis with substance use 35:4, 248 pulmonary renal syndrome 35:9, 494 pulsed dye lasers 35:8, 473 purpura, renal disease 35:7, 357 pyelonephritis acute 35:8, 426, 427 chronic 35:8, 426 pyoderma gangrenosum, inflammatory bowel disease 35:3, 141



Q quinine poisoning 35:12, 652

R radiation nephritis 35:9, 502 radiocontrast agents 35:7, 400 radio-frequency ablation 35:6, 334 radionuclide studies, renal 35:7, 381 radiotherapy colorectal cancer 35:6, 307 oesophageal tumours 35:4, 202 oral mucositis 35:4, 193 Raman spectroscopy 35:6, 331 rectal bleeding, diverticular disease 35:6, 319 reflux nephropathy 35:8, 426 Reiter’s syndrome 35:5, 255 renal abnormalities, genetic 35:7, 386 renal arteries, fibromuscular disease 35:7, 406 renal artery stenosis 35:7, 406 renal biopsy 35:7, 383 image-guided 35:7, 382, 384, 385 renal bone disease 35:8, 450 renal cancer syndromes, familial 35:7, 390 renal disease children 35:7, 393 clinical assessment 35:7, 353



end-stage 35:7, 407 fetal effects 35:9, 527 hypertension 35:7, 404 hypertensive 35:8, 440 inherited 35:7, 393 intrinsic 35:7, 354 liver disease 35:9, 521 maximal conservative management 35:8, 470 metabolic 35:7, 393 paraprotein-related 35:9, 512 pre-conception advice 35:9, 524, 525 pregnancy 35:9, 524 systemic infections 35:9, 507 see also diabetic nephropathy renal failure intrinsic 35:8, 430 paracetamol poisoning 35:12, 643 rhabdomyolysis 35:10, 559 rhabdomyolysis-induced 35:10, 554 see also acute renal failure; chronic kidney disease (chronic renal failure) renal fibrosis 35:8, 444 renal imaging 35:7, 377 renal impairment, subacute 35:7, 355 renal insufficiency, drug metabolism 35:7, 396 renal replacement therapy 35:9, 523 acute renal failure 35:8, 436 chronic kidney disease 35:8, 445 drug dosages 35:7, 398 peritoneal dialysis 35:8, 466 see also haemodialysis renal revascularization 35:7, 408 renal stone disease 35:8, 415, 426 children 35:8, 449 renal transplantation 35:9, 479 assessment 35:7, 382 cardiovascular disease 35:9, 484 developing countries 35:8, 441 donors 35:9, 479 graft dysfunction 35:9, 487 haematological complications 35:9, 485 hypertension 35:7, 405 infections 35:9, 486 malignancy 35:9, 485 medical management 35:9, 483 urinary tract infection 35:8, 428 renal tubular disorders 35:7, 387 renal tubules 35:7, 368, 369, 370 renin–aldosterone–angiotensin system (RAAS) inhibitors 35:7, 399 renin–angiotensin system blockade, diabetic nephropathy 35:9, 504 renovascular disease 35:7, 406

© 2008 Published by Elsevier Ltd.

MEDICINE INDEX VOLUME 35 2007

respiratory acidosis, acute 35:10, 550 respiratory alkalosis, acute 35:10, 550 respiratory function, poisoning 35:10, 558 resuscitation, upper gastrointestinal bleeding 35:3, 160 rhabdomyolysis 35:10, 554 poisoning 35:10, 550, 559 ricin 35:10, 576; 35:12, 651 rimonabant 35:2, 127

S salicylate poisoning 35:12, 654 sarcoidosis, interstitial nephritis 35:9, 501 schistosomiasis 35:9, 509 chronic renal failure 35:8, 441 schizophrenia, substance use 35:4, 248 sclerosing cholangitis, primary 35:2, 83 children 35:2, 69 liver transplantation 35:2, 113 scorpion stings 35:12, 660 sea snakes 35:12, 661 secretory IgA defects 35:5, 261 self-poisoning, deliberate 35:10, 565 serotonin syndrome 35:10, 556 sexually transmitted infections 35:7, 410 short bowel syndrome 35:4, 224, 231 shunt infections 35:9, 508 sicca syndrome, primary biliary cirrhosis 35:2, 81 silicon, kidney damage 35:7, 401 Sjögren’s syndrome, interstitial nephritis 35:9, 501 small bowel disease 35:3, 158 Crohn’s disease differential diagnosis 35:5, 286 small bowel injury, adverse drug reactions 35:4, 213 small bowel ischaemia 35:3, 178 small bowel motility 35:5, 272 irritable bowel syndrome 35:5, 274 smoking chronic kidney disease 35:8, 444 colorectal cancer 35:6, 298 smooth muscle antibody 35:2, 76 snake bites 35:12, 659 sodium calcium edetate 35:10, 563 sodium channel activators 35:12, 651 sodium ions extrarenal control 35:7, 368 poisoning 35:10, 550 sodium nitrite 35:10, 563 sodium thiosulphate 35:10, 564 spider bites 35:12, 661

MEDICINE 36:I

spider naevi 35:1, 2 spinal cord injury, gut dysfunction 35:5, 275 splenomegaly, tropical liver disease 35:1, 53 steatohepatitis, non-alcoholic 35:2, 69, 86 autoimmune hepatitis differential diagnosis 35:2, 77 steatosis 35:1, 26, 27 stents intrahepatic shunt 35:2, 102 luminal 35:6, 334 steroids, cardiotoxic 35:12, 649 Steven–Johnson syndrome 35:4, 190 stomach malignancy 35:3, 158 motility 35:5, 264 stomas 35:6, 311, 314 strontium ranelate 35:2, 126 substance use/misuse 35:10, 570 amphetamines 35:7, 402; 35:11, 582 body packing 35:10, 571 cannabis 35:11, 603 gamma-hydroxybutyric acid 35:11, 619 hazards 35:10, 570 kidney damage 35:7, 402 LSD 35:12, 631 MDMA 35:11, 582 psychiatric comorbidity 35:4, 246 routes 35:10, 570 volatile substances 35:12, 663 see also cocaine; heroin succimer unithiol 35:10, 564 sulphur dioxide poisoning 35:12, 656 sulphur mustard 35:10, 578 superior mesenteric artery, occlusion/stenosis 35:3, 178 syndrome of inappropriate antidiuretic hormone secretion (SIADH) 35:7, 373, 374 syphilis 35:7, 411 syrup of ipecacuanha 35:10, 560 systemic lupus erythematosus (SLE) 35:7, 357 interstitial nephritis 35:9, 501 lupus nephritis 35:9, 516 systemic vasculitis 35:9, 518

thrombotic microangiopathy 35:9, 509 thrombotic thrombocytopenic purpura 35:9, 511 thrombotic thrombocytopenic purpura–haemolytic uraemic syndrome (TTP-HUS) 35:9, 509, 511 thrush, oral 35:4, 192 thyroid hormones 35:2, 125 pregnancy 35:2, 126 thyroxine (T4) 35:2, 125 poisoning 35:12, 658 toiletries, poisoning 35:11, 620 tolvaptan 35:2, 127 tongue black hairy 35:4, 189 fissures 35:4, 189 vitamin B deficiency 35:4, 221 toxic megacolon 35:3, 168 toxic proteins (toxalbumins) 35:12, 651 toxicity 35:10, 542 toxins fungal 35:12, 635 kidney damage 35:7, 401 plant 35:10, 547; 35:12, 649 tropical liver disease 35:1, 50 traditional medicines Chinese herbs nephropathy 35:9, 502 kidney damage 35:7, 401 tramadol 35:12, 641 transferrin receptor 2 deficiency 35:2, 90 transjugular intrahepatic portosystemic shunt (TIPS) 35:2, 102, 103, 106 ascites 35:9, 523 portal hypertension 35:9, 523 upper gastrointestinal bleeding 35:3, 162 triiodothyronine (T3) 35:2, 125 poisoning 35:12, 658 tropical liver disease 35:1, 49 tropical sprue 35:4, 223 tuberculosis 35:1, 56 abdominal 35:5, 257 tubulo-interstitial disorders 35:9, 500 tubulo-interstitial nephritis with uveitis 35:9, 501 tumour-associated glomerular diseases 35:9, 497

T

U

terlipressin 35:9, 523 terrorism, chemical 35:10, 573 abrin 35:10, 577 nerve agents 35:10, 573 ricin 35:10, 576 sulphur mustard 35:10, 578 testosterone, parenteral preparations 35:2, 126 theophylline poisoning 35:12, 657 thin basement membrane nephropathy 35:7, 390 thrombocytopenia, renal transplantation 35:9, 485

ulcerative colitis 35:5, 277 drug-induced exacerbation 35:4, 214 ileal pouch 35:6, 311 malignancy 35:5, 281 mouth disorders 35:4, 192 primary sclerosing cholangitis 35:2, 83 ulcers, prevention 35:4, 209 ultrasonography, renal 35:7, 377, 379 uraemia, cardiovascular disease 35:8, 454



uraemic encephalopathy 35:8, 436 uraemic pericarditis 35:8, 436 urethral syndrome 35:8, 426 urethritis, acute 35:8, 425 urinalysis, dipstick 35:7, 365 urinary tract infection 35:8, 423 antibiotics 35:8, 427 children 35:8, 427 complicated 35:8, 426 vesico-ureteric reflux 35:7, 387 urinary tract obstruction 35:8, 420 urine alkalinization 35:10, 561 pH 35:7, 366 specific gravity 35:7, 366 urobilinogen 35:7, 367 urolithiasis 35:8, 415 uveitis, tubulo-interstitial nephritis with 35:9, 501

V vaccines, development 35:1, 57 vascular lesions, laser therapy 35:8, 473 vasculitis ANCA-associated 35:9, 519, 520 kidney disease 35:7, 357; 35:9, 518 vasopressin 35:3, 163; 35:7, 369 venomous animals 35:12, 659 venous thromboembolism, hormone replacement therapy 35:9, 531 ventilation, poisoning 35:10, 543 vesico-ureteric reflux (VUR) 35:7, 387 viral hepatitis autoimmune hepatitis differential diagnosis 35:2, 77 children 35:2, 67, 68 vitamin B12 deficiency 35:3, 144 mouth disorders 35:4, 192 vitamin K, anticoagulant toxicity 35:12, 664 vitamin K1 35:10, 563 volatile substance abuse 35:12, 663 volume overload, acute renal failure 35:8, 435 volume resuscitation, acute renal failure 35:8, 435

W warfarin poisoning 35:10, 541, 563; 35:12, 648, 664 water reabsorption 35:7, 369 Wegener’s granulomatosis, interstitial nephritis 35:9, 501 Whipple’s disease 35:4, 224 WHO analgesic ladder 35:8, 471 whole-bowel irrigation 35:10, 560 Wilson’s disease 35:2, 69, 93

© 2008 Published by Elsevier Ltd.